[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2018000008A - Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) - Google Patents

Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Info

Publication number
DOP2018000008A
DOP2018000008A DO2018000008A DO2018000008A DOP2018000008A DO P2018000008 A DOP2018000008 A DO P2018000008A DO 2018000008 A DO2018000008 A DO 2018000008A DO 2018000008 A DO2018000008 A DO 2018000008A DO P2018000008 A DOP2018000008 A DO P2018000008A
Authority
DO
Dominican Republic
Prior art keywords
csf
inhibitors
colonia
stimulator factor
factor receiver
Prior art date
Application number
DO2018000008A
Other languages
English (en)
Inventor
Czekaj Mark
Metz Markus
Kothe Michael
Scholte Andrew
L Jr Kane John
Barberis Claude
Erdman Paul
Giese Barret
Liu Jinyu
Ma Liang
Patel Vinod
Shum Patrick
Wei Limli
Le Tieu-Binh
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DOP2018000008A publication Critical patent/DOP2018000008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de fórmulas que son útiles como inhibidores del receptor del factor estimulador de colonias 1 (CSF-1R) (“inhibidores de CSF 1R”).
DO2018000008A 2015-07-20 2018-01-09 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) DOP2018000008A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194619P 2015-07-20 2015-07-20

Publications (1)

Publication Number Publication Date
DOP2018000008A true DOP2018000008A (es) 2018-05-15

Family

ID=56551024

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000008A DOP2018000008A (es) 2015-07-20 2018-01-09 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Country Status (27)

Country Link
US (3) US11274108B2 (es)
EP (1) EP3325471A1 (es)
JP (3) JP6898914B2 (es)
KR (1) KR102665765B1 (es)
CN (1) CN107922396B (es)
AR (1) AR105392A1 (es)
AU (3) AU2016297558B2 (es)
BR (1) BR112018001017B1 (es)
CA (2) CA3217238A1 (es)
CL (1) CL2018000140A1 (es)
CO (1) CO2018001621A2 (es)
CR (1) CR20180109A (es)
DO (1) DOP2018000008A (es)
EC (1) ECSP18012103A (es)
GT (1) GT201800020A (es)
IL (3) IL305843B1 (es)
MA (1) MA42023B2 (es)
MX (2) MX2018000880A (es)
MY (1) MY186368A (es)
PE (1) PE20180573A1 (es)
PH (1) PH12018500140A1 (es)
RU (1) RU2748884C2 (es)
SG (1) SG10201912699RA (es)
TN (1) TN2018000020A1 (es)
TW (1) TWI734693B (es)
WO (1) WO2017015267A1 (es)
ZA (1) ZA201800082B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
KR20200009088A (ko) 2017-05-23 2020-01-29 메이 파마, 아이엔씨. 병용 요법
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
AU2018318129A1 (en) 2017-08-14 2020-03-26 Mei Pharma, Inc. Combination therapy
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
SG11202109997PA (en) * 2019-03-29 2021-10-28 Kowa Co Novel azaindole derivative
WO2022020342A1 (en) 2020-07-20 2022-01-27 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
WO2022057895A1 (en) * 2020-09-21 2022-03-24 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
TW202241888A (zh) 2020-12-23 2022-11-01 美商健臻公司 氘化群落刺激因子-1受體(csf-1r)抑制劑
WO2023249989A1 (en) 2022-06-22 2023-12-28 Genzyme Corporation Solid forms of deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612323A (en) * 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS61151176A (ja) * 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
WO1994000450A1 (en) * 1992-06-25 1994-01-06 Zeneca Limited Chromanderivatives as angiotensin ii antagonists
FR2693197B1 (fr) * 1992-07-03 1994-09-23 Synthelabo Nouveaux dérivés de quinoléine, leur procédé de préparation et leur application thérapeutique.
KR0173172B1 (ko) * 1992-12-17 1999-02-01 알렌 제이. 스피겔 Crf 길항제로서의 피롤로피리미딘
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
JPH09202774A (ja) * 1996-01-25 1997-08-05 Green Cross Corp:The ２−アリールキノリン類およびその製造方法
JPH101471A (ja) * 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
CA2264101A1 (en) * 1996-08-30 1998-03-05 Yoshitomi Pharmaceutical Industries Ltd. Preventives/remedies for muscle tissue degenerations
AU745081B2 (en) * 1997-06-27 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
MY132871A (en) * 1997-07-03 2007-10-31 Bristol Myers Squibb Pharma Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6130333A (en) * 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
US6743793B2 (en) * 2000-03-09 2004-06-01 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
US7135495B2 (en) * 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
JP2005530745A (ja) * 2002-05-02 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
CN1742007A (zh) * 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
DE10342503A1 (de) 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
JP2007505933A (ja) 2003-09-18 2007-03-15 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０インヒビターとしての新規なヘテロ環化合物
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
US20060058339A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
AU2005280739B2 (en) * 2004-09-03 2010-11-11 Yuhan Corporation Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof
TWI278682B (en) 2004-11-23 2007-04-11 Ind Tech Res Inst Fiber optic interferometric position sensor and measuring method thereof
CN101193867A (zh) 2004-12-01 2008-06-04 Osi医药有限公司 N取代的苯并咪唑基c-Kit抑制剂和苯并咪唑组合库
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
WO2007013896A2 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
AU2006261993B2 (en) 2005-06-22 2011-11-17 Plexxikon, Inc. Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
SI2081937T1 (sl) 2006-10-23 2012-11-30 Sgx Pharmaceuticals Inc Triazolopiridazinski modulatorji proteinskih kinaz
WO2008064219A1 (en) * 2006-11-22 2008-05-29 Johnson Controls Technology Company Multichannel evaporator with flow mixing manifold
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101641351A (zh) * 2006-12-21 2010-02-03 普莱希科公司 用于激酶调节的化合物和方法及其适应症
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US8119658B2 (en) * 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2010124108A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
RU2013127637A (ru) * 2010-11-24 2014-12-27 Аллерган, Инк. Индольные производные в качестве модуляторов рецепторов s1p
US20130324526A1 (en) * 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
JP2014515368A (ja) * 2011-05-26 2014-06-30 第一三共株式会社 プロテインキナーゼ阻害剤としての複素環化合物
US8609653B2 (en) * 2011-07-15 2013-12-17 Glaxosmithkline Llc Azaindole compounds and methods for treating HIV
PT2766359T (pt) * 2011-10-14 2016-07-14 Ambit Biosciences Corp Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
KR20140088887A (ko) * 2011-11-03 2014-07-11 머크 샤프 앤드 돔 코포레이션 mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도
WO2013116182A1 (en) * 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
WO2014081820A1 (en) * 2012-11-20 2014-05-30 Discoverybiomed, Inc. Small molecule cftr correctors
TWI663159B (zh) * 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
MX362341B (es) 2014-05-01 2019-01-11 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7.

Also Published As

Publication number Publication date
TWI734693B (zh) 2021-08-01
RU2748884C2 (ru) 2021-06-01
IL276292B2 (en) 2024-02-01
JP7401482B2 (ja) 2023-12-19
MA42023B2 (fr) 2022-01-31
IL305843A (en) 2023-11-01
CO2018001621A2 (es) 2018-02-28
SG10201912699RA (en) 2020-02-27
CA3217238A1 (en) 2017-01-26
KR102665765B1 (ko) 2024-05-10
JP6898914B2 (ja) 2021-07-07
BR112018001017B1 (pt) 2024-02-15
BR112018001017A2 (pt) 2018-09-18
MY186368A (en) 2021-07-16
IL276292B1 (en) 2023-10-01
IL256964A (en) 2018-03-29
AR105392A1 (es) 2017-09-27
RU2018106060A (ru) 2019-08-20
KR20180030199A (ko) 2018-03-21
PE20180573A1 (es) 2018-04-04
US20190016707A1 (en) 2019-01-17
JP2024028845A (ja) 2024-03-05
ZA201800082B (en) 2018-12-19
AU2021204116B2 (en) 2022-12-01
PH12018500140A1 (en) 2018-07-23
CN107922396B (zh) 2022-08-05
TN2018000020A1 (en) 2019-07-08
CR20180109A (es) 2018-05-03
AU2016297558A1 (en) 2018-03-08
US20240217991A1 (en) 2024-07-04
JP2021107414A (ja) 2021-07-29
CN107922396A (zh) 2018-04-17
WO2017015267A1 (en) 2017-01-26
MX2021015102A (es) 2022-02-21
TW201716393A (zh) 2017-05-16
GT201800020A (es) 2019-10-21
JP2018524381A (ja) 2018-08-30
IL256964B (en) 2021-10-31
RU2018106060A3 (es) 2019-12-13
IL305843B1 (en) 2024-09-01
CL2018000140A1 (es) 2018-08-17
NZ739951A (en) 2024-02-23
AU2021204116A1 (en) 2021-07-15
IL276292A (en) 2020-09-30
AU2023201013A1 (en) 2023-03-23
ECSP18012103A (es) 2018-04-30
EP3325471A1 (en) 2018-05-30
US20220396588A1 (en) 2022-12-15
US11274108B2 (en) 2022-03-15
AU2016297558B2 (en) 2021-03-25
CA2993018A1 (en) 2017-01-26
MX2018000880A (es) 2018-08-24

Similar Documents

Publication Publication Date Title
DOP2018000008A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
ZA202307128B (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
MX2018006148A (es) Inhibidores de cxcr2.
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
MX2016014765A (es) Incremento del rendimiento utilizando soforolipidos.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
IN2014MU00069A (es)
UA104379U (uk) Біс(оксифеніленімінометилен)дифеноли з перфторованими моно- та біфеніленовими центральними фрагментами як прекурсори для синтезу бензоксазинів